The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2025 | DESTINY-Gastric05: first-line T-DXd ± pembrolizumab in HER2+ gastric cancer
Kohei Shitara, MD, National Cancer Center Hospital East, Kashiwa, Japan, comments on the design of the Phase III DESTINY-Gastric05 trial (NCT06731478), comparing first-line trastuzumab deruxtecan (T-DXd) plus chemotherapy with or without pembrolizumab versus standard trastuzumab-based regimens in HER2-positive unresectable or metastatic gastric or gastroesophageal junction cancer. The study targets patients with PD-L1 CPS ≥1, aiming to assess progression-free and overall survival outcomes. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
